Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Because the HBV reverse transcriptase lacks a proofreading function, many HBV genotypes, subgenotypes, mutants, and recombinants exist. At least 10 HBV genotypes (HBV-A through J) with distinct geographic distributions have been identified; by definition, their complete genomic sequences diverge by more than 8%. HBV genotype is increasingly becoming recognized as an important factor in the progression and clinical outcome of HBVinduced disease. Infections by HBV-C or -D are significantly more likely to lead to cirrhosis and hepatocellular carcinoma than are infections by HBV-A or -B. Additionally, the hepatitis B e antigen seroconversion response to standard or pegylated interferon is more favorable in patients with HBV-A or -B than in those with HBV-C or -D. However, therapeutic responses to nucleos(t)ide analogues are generally comparable among HBV genotypes. In conclusion, genotyping of HBV is useful in identifying chronic hepatitis B patients who are at increased risk of disease progression, thereby enabling physicians to optimize antiviral therapy for these patients.
IntRoDuCtIon
Although safe and effective vaccines for hepatitis B virus (HBV) have been available for more than two decades, infection by this organism remains a burden to global public health, resulting in 600,000 to 1 million deaths per year worldwide [1] . Clinically, HBV infection can manifest in acute/fulminant hepatitis or in various chronic conditions, including an inactive carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) [2] . Approximately 15-40% of HBV carriers who acquire the virus early in life eventually develop HBV-related cirrhosis or HCC [3] .
Being a virus of the family Hepadnaviridae, HBV is the smallest human DNA virus, carrying a genome only 3, 200 nucleotides in length [4] . The partially double-stranded circular DNA harbors four overlapping open reading frames encoding the S (surface), C (core), P (polymerase), and X genes ( /site per year [4] . This unique replication strategy accounts for the majority of the point mutations, deletions, and insertions observed in the HBV genome.
The lengthy evolution of HBV has led to the present existence of various genotypes, subgenotypes, mutants, recombinants, and even quasispecies of HBV [5] .
EpIDEMIology AnD DIsEAsE pRogREssIon of HBV InfECtIon
HBV is endemic in Asia and the Pacific islands, Africa, Southern Europe, and Latin America. The community prevalence of the HBV surface antigen (HBsAg) encoded by gene S ranges from 2 to 20% [1] . In Asian countries, the majority of HBV infections are acquired perinatally or in early childhood by the age of 2 years through vertical (mother-to-child) transmission; however, horizontal transmission is the main route of infection in African and Western countries [1] .
Disease progression in patients with chronic hepatitis B varies widely. Several viral factors, including the HBV genotype, viral load, and specific viral mutations, have been documented to be strongly associated with disease progression and outcomes (Table 1) . The annual incidence of cirrhosis is estimated to be 2-6% in those who test positive for the HBV e antigen (HBeAg) and 8-10% in those who test negative. The annual incidence of HCC is less than 1% for patients without cirrhosis and 2-3% for patients with cirrhosis [2, 3] .
MolECulAR EpIDEMIology of HBV gEnotypEs AnD suBtypEs
Analyses of the divergence of HBV genomic sequences has led to the identification of 10 HBV genotypes (A through J) and several subtypes, where separate genotypes and subtypes are defined as strains exhibiting an entire genome sequence divergence of more than 8% or 4-8%, respectively [6] . The geographic distribution of HBV genotypes A-H and their subtypes is shown in Table   2 . Genotype A is highly prevalent in sub-Saharan Africa (subtype A1), Northern Europe (subtype A2), and Western Africa (subtype A3). Genotypes B and C are prevalent in the Asian Pacific region. However, the prevalence rates of genotypes B and C vary among the different Asian countries (Table 3 ) [7] . For example, HBV-C is more common than HBV-B in China, Japan, and Korea, whereas HBV-B is the more common genotype in Taiwan and Vietnam [8] .
Of particular note is the fact that almost all chronic hepatitis B patients in Korea are infected with HBV-C [7] .
Genotype B has six subtypes, B1-B6. B1 is found in Japan; B2-B5 and B7 are found in East Asia, and B6 is found in indigenous populations living in Arctic regions, including Alaska, Northern Canada, and Greenland. Genotype C, which has subtypes C1-C5, is found primarily in East and Southeast Asia. Genotype D, which has subtypes D1-D5, is prevalent in Africa, Europe, the Mediterranean region, and India. Genotype E is restricted to West Africa. Genotype F, which has 4 subtypes (F1-F4), is found in Central and South America. Genotype G has been reported in France, Germany, and the United States. Genotype H is found in Central America [9, 10] . Recently, genotype I was isolated in Vietnam and Laos [11] , and genotype J was identified in Japan [12] .
HBV gEnotypE AnD DIsEAsE pRogREssIon In pAtIEnts wItH CHRonIC HEpAtItIs B
Current evidence for the impact of HBV genotype on the short-and long-term adverse outcomes of chronic HBV infection is summarized in Table 4 . Most retrospective and case-control studies have indicated that patients infected with HBV-C have more severe liver disease, including cirrhosis and HCC, than those with infected with HBV-B [2, 8, 13] . In a recent community-based prospective cohort study of 2762 Taiwanese HBV carriers, HBV-C was associated with a higher risk of HCC than was HBV-B; the adjusted hazard ratio was 2.35 (95% confidence interval
[CI], 1.68 to 3.30; p < 0.001) [14] . These findings confirm that HBV-C is associated with a higher risk of HCC development than HBV-B is. 
MolECulAR MECHAnIsMs of HBV gEnotypE-spECIfIC pAtHogEnEsIs
The pathogenic differences among various HBV geno- Table 5 .
HBV gEnotypE AnD AntI-VIRAl tREAtMEnts

Interferon-based therapy
The therapeutic endpoints for the management of Recent studies have suggested that HBV genotype affects the therapeutic response to both IFN and nucleos(t)-ide analogue-based agents [23, 24] . In brief, the incidence of sustained ALT normalization and HBeAg seroconver- IFN therapy is thus not recommended for these patients [37] .
therapy with nucleoside or nucleotide analogues
In most clinical studies, the therapeutic responses to lamivudine, adefovir, entecavir, and telbivudine have been similar among the different HBV genotypes [5, 8, 23, 24] , and a recent meta-analysis found no significant association between HBV genotype and the response to nucleos(t)-ide analogues [35] . Although HBV genotypes seem to have little impact on the response to nucleos(t)ide analogue treatment [36] , our retrospective analysis has suggested that genotype B is independently associated with earlier detection of lamivudine resistance. Additionally, we found that the development of lamivudine resistance within the first 12 months of lamivudine therapy had a significantly higher association with genotype B than with genotype C (odds ratio, 8.27; p = 0.004) [38] . Therefore, more fre quent monitoring of genotypic resistance might be needed for specific HBV genotypes during nucleos(t)ide analogue therapy.
Complete clearance of HBsAg is rare in chronic hepatitis B patients treated with oral agents. However, Marcellin et al. [39] recently reported that complete HBsAg clearance occurred in five of 158 HBeAg-positive patients after 48
weeks of treatment with tenofovir disoproxil. Of these five
Caucasian patients, two were infected with HBV-A, and three were infected with HBV-D. Although the proportion of patients with HBsAg loss was too small to reach any definite conclusions, the association of HBV genotype with nucleos(t)ide analogue-induced HBsAg clearance is interesting and deserves further study. 
